@article{2e5f06c1ee6648f197ea9c030092571b,
title = "Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma",
abstract = "BACKGROUND: Autologous hematopoietic cell transplantation (auto-HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL); however, long-term outcomes are not well described. METHODS: This study analyzed survival, nonrelapse mortality, late effects, and subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression-free for ≥2 years after auto-HCT for cHL or DLBCL between 1990 and 2008. The median age at auto-HCT was 40 years; the median follow-up was 10.6 years. RESULTS: The 5-year overall survival rate was 90% (95% confidence interval [CI], 87%-92%) for patients with cHL and 89% (95% CI, 87%-91%) for patients with DLBCL. The risk of late mortality in comparison with the general population was 9.6-fold higher for patients with cHL (standardized mortality ratio [SMR], 9.6) and 3.4-fold higher for patients with DLBCL (SMR, 3.4). Relapse accounted for 44% of late deaths. At least 1 late effect was reported for 9% of the patients. A total of 105 SMNs were confirmed: 44 in the cHL group and 61 in the DLBCL group. According to a multivariate analysis, older age, male sex, a Karnofsky score < 90, total body irradiation (TBI) exposure, and a higher number of lines of chemotherapy before auto-HCT were risk factors for overall mortality in cHL. Risk factors in DLBCL were older age and TBI exposure. A subanalysis of 798 adolescent and young adult patients mirrored the outcomes of the overall study population. CONCLUSIONS: Despite generally favorable outcomes, 2-year survivors of auto-HCT for cHL or DLBCL have an excess late-mortality risk in comparison with the general population and experience an assortment of late complications. Cancer 2018;124:816-25.",
author = "Myers, {Regina M.} and Hill, {Brian T.} and Shaw, {Bronwen E.} and Soyoung Kim and Millard, {Heather R.} and Minoo Battiwalla and Majhail, {Navneet S.} and David Buchbinder and Lazarus, {Hillard M.} and Savani, {Bipin N.} and Flowers, {Mary E.D.} and Anita D'Souza and Ehrhardt, {Matthew J.} and Amelia Langston and Yared, {Jean A.} and Hayashi, {Robert J.} and Andrew Daly and Olsson, {Richard F.} and Yoshihiro Inamoto and Malone, {Adriana K.} and Zachariah DeFilipp and Margossian, {Steven P.} and Warwick, {Anne B.} and Samantha Jaglowski and Amer Beitinjaneh and Henry Fung and Kasow, {Kimberly A.} and Marks, {David I.} and Jana Reynolds and Keith Stockerl-Goldstein and Baldeep Wirk and Wood, {William A.} and Mehdi Hamadani and Prakash Satwani",
note = "Funding Information: The Center for International Blood and Marrow Transplant Research is supported by the following: the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases (Public Health Service grant/cooperative agreement 5U24-CA076518); the National Cancer Institute and the National Heart, Lung, and Blood Institute (grant/cooperative agreement 5U10HL069294); the Health Resources and Services Administration (contract HHSH250201200016C); the Office of Naval Research (grants N00014-15-1-0848 and N00014-16-1-2020); Actinium Pharmaceuticals, Inc (corporate member); Alexion; Amgen, Inc (corporate member); an anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc; the Be the Match Foundation; Bluebird Bio, Inc (corporate member); Bristol-Myers Squibb Oncology (corporate member); Celgene Corporation (corporate member); Cellular Dynamics International, Inc; Cerus Corporation; Chimerix, Inc (corporate member); the Fred Hutchinson Cancer Research Center; Gamida Cell, Ltd; Genentech, Inc; Genzyme Corporation; Gilead Sciences, Inc; Health Research, Inc; the Roswell Park Cancer Institute; His-toGenetics, Inc; Incyte Corporation; Janssen Scientific Affairs, LLC; Jazz Pharmaceuticals, Inc (corporate member); the Jeff Gordon Children{\textquoteright}s Foundation; the Leukemia & Lymphoma Society; Medac, GmbH; MedImmune; the Medical College of Wisconsin; Merck & Co, Inc (corporate member); Mesoblast (corporate member); MesoScale Diagnostics, Inc; Miltenyi Biotec, Inc (corporate member); the National Marrow Donor Program; Neovii Biotech NA, Inc; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc; Otsuka America Pharmaceutical, Inc; Otsuka Pharmaceutical Co, Ltd (Japan); the Patient-Centered Outcomes Research Institute; PerkinElmer, Inc; Pfizer, Inc; Sanofi US (corporate member); Seattle Genetics (corporate member); Spectrum Pharmaceuticals, Inc (corporate member); the St. Baldrick{\textquoteright}s Foundation; Sunesis Pharmaceuticals, Inc (corporate member); Swedish Orphan Biovitrum, Inc; Takeda Oncology; Telomere Diagnostics, Inc; the University of Minnesota; and WellPoint, Inc (corporate member). The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US Government. Funding Information: The Center for International Blood and Marrow Transplant Research is supported by the following: the National Cancer Institute, the National Heart, Lung, and Blood Institute, and the National Institute of Allergy and Infectious Diseases (Public Health Service grant/cooperative agreement 5U24-CA076518); the National Cancer Institute and the National Heart, Lung, and Blood Institute (grant/cooperative agreement 5U10HL069294); the Health Resources and Services Administration (contract HHSH250201200016C); the Office of Naval Research (grants N00014-15-1-0848 and N00014-16-1-2020); Actinium Pharmaceuticals, Inc (corporate member); Alexion; Amgen, Inc (corporate member); an anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc; the Be the Match Foundation; Bluebird Bio, Inc (corporate member); Bristol-Myers Squibb Oncology (corporate member); Celgene Corporation (corporate member); Cellular Dynamics International, Inc; Cerus Corporation; Chimerix, Inc (corporate member); the Fred Hutchinson Cancer Research Center; Gamida Cell, Ltd; Genentech, Inc; Genzyme Corporation; Gilead Sciences, Inc; Health Research, Inc; the Roswell Park Cancer Institute; HistoGenetics, Inc; Incyte Corporation; Janssen Scientific Affairs, LLC; Jazz Pharmaceuticals, Inc (corporate member); the Jeff Gordon Children's Foundation; the Leukemia & Lymphoma Society; Medac, GmbH; MedImmune; the Medical College of Wisconsin; Merck &f Co, Inc (corporate member); Mesoblast (corporate member); MesoScale Diagnostics, Inc; Miltenyi Biotec, Inc (corporate member); the National Marrow Donor Program; Neovii Biotech NA, Inc; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Healthcare Solutions, Inc; Otsuka America Pharmaceutical, Inc; Otsuka Pharmaceutical Co, Ltd (Japan); the Patient-Centered Outcomes Research Institute; PerkinElmer, Inc; Pfizer, Inc; Sanofi US (corporate member); Seattle Genetics (corporate member); Spectrum Pharmaceuticals, Inc (corporate member); the St. Baldrick's Foundation; Sunesis Pharmaceuticals, Inc (corporate member); Swedish Orphan Biovitrum, Inc; Takeda Oncology; Telomere Diagnostics, Inc; the University of Minnesota; and WellPoint, Inc (corporate member). The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US Government. Publisher Copyright: {\textcopyright} 2017 American Cancer Society",
year = "2018",
month = feb,
day = "15",
doi = "10.1002/cncr.31114",
language = "English (US)",
volume = "124",
pages = "816--825",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",
}